You just read:

EnGeneIC Doses First Patient in U.S. Phase 1 Clinical Study of Targeted EDV™ Nanocells in Recurrent Glioblastoma Multiforme

News provided by

EnGeneIC Limited

Mar 21, 2017, 08:20 ET